Skip to content
Disclosery

REGENERON PHARMACEUTICALS, INC.

Follow

13F filer, CIK 872589, TARRYTOWN, NY

REGENERON PHARMACEUTICALS, INC. reported $47,884,476 across 2 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-08.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-26-057922

Period
2026-03-31
Reported value
$47.9M
Holdings
2
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001104659-26-057922, largest first. % of portfolio is the value over $47,884,476, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NTLAINTELLIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,702,995 shares; 2025Q1: 3,702,995 shares; 2025Q2: 3,702,995 shares; 2025Q3: 3,702,995 shares; 2025Q4: 3,702,995 shares; 2026Q1: 3,702,995 shares 3,702,995$47.5M99.14%0Timeline
ADICET BIO INCADICET BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 968,183 shares; 2025Q1: 968,183 shares; 2025Q2: 968,183 shares; 2025Q3: 968,183 shares; 2025Q4: 60,511 shares; 2026Q1: 60,511 shares 60,511$412K0.86%0

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-057922 base2026-05-08acceptance time not in the bulk data set